A recombinant modified vaccinia Ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
Authors
Taylor, GJia, H
Harrington, K
Lee, Lip W
Turner, J
Ladell, K
Price, D
Tanday, M
Matthews, J
Roberts, C
Edwards, C
McGuigan, L
Hartley, A
Wilson, S
Hui, E
Chan, A
Rickinson, A
Steven, N
Affiliation
Cancer Research UK Centre, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom.Issue Date
2014-08-14
Metadata
Show full item recordAbstract
Epstein-Barr virus (EBV) is associated with several cancers in which the tumor cells express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost immunity to these tumor antigens. A phase I trial was conducted to demonstrate the safety and immunogenicity of MVA-EL across a range of doses.Citation
A recombinant modified vaccinia Ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. 2014: Clin Cancer ResJournal
Clinical Cancer ResearchDOI
10.1158/1078-0432.CCR-14-1122-TPubMed ID
25124688Type
ArticleLanguage
enISSN
1078-0432ae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-14-1122-T
Scopus Count
Collections
Related articles
- Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.
- Authors: Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, Stocken DD, Rickinson AB, Steven NM, Chan AT
- Issue date: 2013 Mar 15
- Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
- Authors: Taylor GS, Haigh TA, Gudgeon NH, Phelps RJ, Lee SP, Steven NM, Rickinson AB
- Issue date: 2004 Jan
- Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas.
- Authors: Rühl J, Citterio C, Engelmann C, Haigh T, Dzionek A, Dreyer J, Khanna R, Taylor GS, Wilson JB, Leung CS, Münz C
- Issue date: 2019 May 1
- Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
- Authors: Eom HS, Choi BK, Lee Y, Lee H, Yun T, Kim YH, Lee JJ, Kwon BS
- Issue date: 2016 Apr
- Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
- Authors: Lünemann JD, Edwards N, Muraro PA, Hayashi S, Cohen JI, Münz C, Martin R
- Issue date: 2006 Jun